On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.

On June 13, 2024, Novavax, Inc. held its Annual Meeting where several key proposals were voted upon by stockholders. The stockholders approved the amendment and restatement of the Amended and Restated 2015 Stock Incentive Plan, which will increase the available shares for issuance by 6,500,000. Additionally, the 2013 Employee Stock Purchase Plan was amended and restated to increase the available shares by 1,000,000. The stockholders also elected three Class II directors to serve a three-year term, approved the executive compensation for 2023, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposals were detailed in the 2024 Proxy Statement filed with the SEC on April 29, 2024, and amended on June 5, 2024. The full text of the amended plans is incorporated into the Current Report on Form 8-K as exhibits.